Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

• Published in: Science (American Association for the Advancement of Science) Vol. 375; no. 6581; pp. 678 - 680
• Main Authors: Muik, Alexander, Lui, Bonny Gaby, Wallisch, Ann-Kathrin, Bacher, Maren, Mühl, Julia, Reinholz, Jonas, Ozhelvaci, Orkun, Beckmann, Nina, Güimil Garcia, Ramón de la Caridad, Poran, Asaf, Shpyro, Svetlana, Finlayson, Andrew, Cai, Hui, Yang, Qi, Swanson, Kena A., Türeci, Özlem, Şahin, Uğur
• Format: Journal Article
• Language: English
• Published: United States The American Association for the Advancement of Science 11.02.2022
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; BNT162 Vaccine - administration & dosage; BNT162 Vaccine - immunology; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 - virology; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Humans; Immunization Schedule; Immunization, Secondary; Middle Aged; mRNA; Mutation; Neutralization; Neutralization Tests; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; T-Lymphocytes - immunology; Vaccination; Vaccines; Viral diseases; Young Adult

The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 refere...